Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors

Trial Profile

Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2016

At a glance

  • Drugs Everolimus (Primary) ; Doxorubicin; Ethiodized oil
  • Indications Gastrointestinal cancer; Liver metastases; Neuroendocrine tumours
  • Focus Therapeutic Use
  • Acronyms EVACEL
  • Most Recent Events

    • 02 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 03 Jul 2013 New information source identified and integrated EudraCT2012-002224-32 record
    • 01 Oct 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top